ERIS Lifesciences Ltd Share Price

1,048.7
(1.10%)
Jul 24, 2024|03:32:22 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open1,031.95
  • Day's High1,055.2
  • 52 Wk High1,090
  • Prev. Close1,037.3
  • Day's Low1,021.8
  • 52 Wk Low745
  • Turnover (lac)709.02
  • P/E47
  • Face Value1
  • Book Value185.31
  • EPS22.03
  • Mkt. Cap (Cr.)14,270.19
  • Div. Yield0
No Records Found

ERIS Lifesciences Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

1,031.95

Prev. Close

1,037.3

Turnover(Lac.)

709.02

Day's High

1,055.2

Day's Low

1,021.8

52 Week's High

1,090

52 Week's Low

745

Book Value

185.31

Face Value

1

Mkt Cap (₹ Cr.)

14,270.19

P/E

47

EPS

22.03

Divi. Yield

0

ERIS Lifesciences Ltd Corporate Action

14 May 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

2 Sep 2023

12:00 AM

BookCloser

arrow

7 Aug 2023

12:00 AM

AGM

Announcement Date: 07 Aug, 2023

arrow

ERIS Lifesciences Ltd NEWS AND UPDATE

Top 10 stocks for today - 16th July, 2024
16 Jul 2024|08:47 AM

Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Birla Estates, Lupin, etc.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

ERIS Lifesciences Ltd SHAREHOLDING SNAPSHOT

24 Jul, 2024|03:01 AM
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 54.88%

Foreign: 0.00%

Indian: 54.88%

Non-Promoter- 30.81%

Institutions: 30.81%

Non-Institutions: 14.29%

Custodian: 0.00%

Share Price

ERIS Lifesciences Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2023Mar-2022Mar-2021Mar-2020

Equity Capital

13.6

14.04

13.58

13.58

Preference Capital

0

0

0

0

Reserves

2,208.29

1,904.51

1,561.89

1,286.12

Net Worth

2,221.89

1,918.55

1,575.47

1,299.7

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

1,215.73

1,108.83

1,020.23

760.6

yoy growth (%)

9.64

8.68

34.13

6.69

Raw materials

-199.65

-198.51

-164.35

-108.42

As % of sales

16.42

17.9

16.1

14.25

Employee costs

-222.18

-207.01

-191.73

-130.84

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

458.53

388.89

323.59

311.88

Depreciation

-51.45

-37.64

-44.88

-21.79

Tax paid

-41.34

-38.28

-32.31

-18.23

Working capital

85.45

2.88

111.28

52.44

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

9.64

8.68

34.13

6.69

Op profit growth

15.97

17.35

12.57

16.5

EBIT growth

18.44

19.73

0.97

17.3

Net profit growth

18.99

20.36

-0.81

18.34

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

1,991.3

1,661.82

1,326.17

1,192.64

1,058.18

Excise Duty

0

0

0

0

0

Net Sales

1,991.3

1,661.82

1,326.17

1,192.64

1,058.18

Other Operating Income

17.85

23.33

20.88

19.22

15.88

Other Income

23.82

11.15

26.09

8.71

15.4

ERIS Lifesciences Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,601.6

125.973,84,469.44867.60.845,536.9998.75

Cipla Ltd

CIPLA

1,497.9

32.551,20,921.781,038.40.573,444.92346.41

Divis Laboratories Ltd

DIVISLAB

4,527

76.161,19,967.915310.662,259507.93

Zydus Lifesciences Ltd

ZYDUSLIFE

1,148.85

33.631,15,601.191,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,865

26.731,14,525.251,034.80.585,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

MORE ABOUT ERIS Lifesciences Ltd

Management

Register Office

Registrar Office

CMD & Executive Director

Amit Indubhushan Bakshi

WTD & Executive Director

Kaushal Kamlesh Shah

WTD & Executive Director

Inderjeet Singh Negi

Executive Director / WTD / Chi

Krishnakumar Vaidyanathan

Independent Non Exe. Director

Sujesh Vasudevan

Independent Non Exe. Director

Prashant Gupta

Independent Non Exe. Director

Rajeev Narotam Dalal

Independent Non Exe. Director

Kalpana Unadkat

Registered Office


Tel: -

Website: -

Email: -

Registrar Office


Tel: -

Website: -

Email: -

Summary

Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to Eris Lifesciences Private Limited on February 9, 2007. Further, the Company was converted into a Public Limited cCompany and the name was changed to Eris Lifesciences Limited on February 2, 2017. The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this, it has a portfolio of 112 Mother Brands across therapy areas. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. Its operations are supported by a distribution network of 22 Sales depots, 2,059 Stockists and more than 5,00,000 retail chemists.In 2007, the company launched Eris division focused on cardiology and diabetes segment. In 2008, the company launched Nikkos division focused on gastroenterology and orthopedics segment. In 2009, the company launched Adura division focused on cardiology and diabetes
Read More

Company FAQs

What is the ERIS Lifesciences Ltd share price today?

Down Arrow

The ERIS Lifesciences Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1048.7 today.

What is the Market Cap of ERIS Lifesciences Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of ERIS Lifesciences Ltd is ₹14270.19 Cr. as of 24 Jul ‘24

What is the PE and PB ratio of ERIS Lifesciences Ltd?

Down Arrow

The PE and PB ratios of ERIS Lifesciences Ltd is 47 and 5.58 as of 24 Jul ‘24

What is the 52 Week High and Low of ERIS Lifesciences Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a ERIS Lifesciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of ERIS Lifesciences Ltd is ₹745 and ₹1090 as of 24 Jul ‘24

What is the CAGR of ERIS Lifesciences Ltd?

Down Arrow

ERIS Lifesciences Ltd's CAGR for 5 Years at 20.56%, 3 Years at 10.79%, 1 Year at 37.59%, 6 Month at 17.88%, 3 Month at 17.47% and 1 Month at -0.28%.

What is the shareholding pattern of ERIS Lifesciences Ltd?

Down Arrow

The shareholding pattern of ERIS Lifesciences Ltd is as follows:
Promoters - 54.88 %
Institutions - 30.82 %
Public - 14.30 %

Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.